Home News Global Markets

MPM Capital raises US$850 mil for cancer fund, with US$650 million from UBS

The Edge Singapore
The Edge Singapore10/6/2021 4:45 PM GMT+08  • 2 min read
MPM Capital raises US$850 mil for cancer fund, with US$650 million from UBS
UBS clients have invested more than US$1 billion to seek out cancer treatments.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

MPM Capital is a biotechnology investment firm, recently raised US$850 million for its Oncology Impact Fund 2, meant to further research by companies trying to come up with cures for cancer.

Out of this total, the bulk of it, some US$650 million, were from clients of UBS global wealth management.

The amount raised for OIF2 makes it the largest dedicated impact investment fund in biotech history.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.